Divi’s Laboratories shares in focus as weight loss drug receives EU panel backing

Analysts believe Divi’s Laboratories is likely to be the intermediate supplier of orforglipron for weight loss. The stock may see a reaction in today’s trading session.

Leave a Reply

Your email address will not be published. Required fields are marked *